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Background: Treatment with an inhaled corticosteroid (ICS) and long-acting bronchodilator is
recommended for severe/very severe chronic obstructive pulmonary disease (COPD) patients
with repeated exacerbations. This randomized, double-blind, double-dummy, parallel-group,
12-month multicenter study evaluated the effect of budesonide/formoterol pressurized
metered-dose inhaler (pMDI) on COPD exacerbations.
Methods: Following a 2-week run-in during which COPD patients aged 40 years with an exac-
erbation history discontinued medications except ICSs, 1219 patients were randomized 1:1:1 to
twice-daily budesonide/formoterol pMDI 320/9 mg, budesonide/formoterol pMDI 160/9 mg, or
formoterol dry powder inhaler 9 mg. An exacerbation was defined as COPD worsening requiring
oral corticosteroids and/or hospitalization. A post hoc analysis, with antibiotic treatment
added to the exacerbation definition, was also performed.
Results: Budesonide/formoterol 320/9 and 160/9 reduced exacerbation rates (number per
patient-treatment year) by 34.6% and 25.9%, respectively, versus formoterol (p  0.002).
Budesonide/formoterol 320/9 prolonged time to first exacerbation versus formoterol, corre-
sponding to a 21.2% reduction in hazard ratio (0.788 [95% CI: 0.639, 0.972]; p Z 0.026). Exac-
erbation rates (number per patient-treatment year) including antibiotic treatment (post hoc
analysis) were reduced by 25.9% and 18.7% with budesonide/formoterol 320/9 and 160/9,
respectively, versus formoterol (p  0.023). Both budesonide/formoterol doses were well
tolerated with safety profiles similar to formoterol. Pneumonia adverse events occurred in
6.4%, 4.7%, and 2.7% of patients in the budesonide/formoterol 320/9, 160/9, and formoterol
groups.794 7668; fax: þ1 713 794 7295.
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258 A. Sharafkhaneh et al.Conclusions: Over 12 months, both budesonide/formoterol doses reduced the exacerbation
rate (defined with or without antibiotic treatment) versus formoterol. Budesonide/formoterol
pMDI is an appropriate treatment for reducing exacerbations in COPD patients with a history of
exacerbations. (NCT00419744).
Published by Elsevier Ltd.Introduction
Although a standard definition has not been established,1
the Global Initiative for Chronic Obstructive Lung Disease
(GOLD) guidelines define an exacerbation of chronic
obstructive pulmonary disease (COPD) as “an event in the
natural course of the disease characterized by a change in
the patient’s baseline dyspnea, cough, and/or sputum that
is beyond normal day-to-day variations, is acute in onset,
and may warrant a change in regular medication in
a patient with underlying COPD.2 Increasing frequency of
COPD exacerbations are an indication of increased disease
severity2 and have been associated with pulmonary func-
tion decline,3,4 reduced quality of life,5 and increased
mortality.6 Moreover, severe exacerbations of COPD are
associated with increased health care utilization7 and costs
compared with mild or moderate exacerbations.7,8
Preventing and treating exacerbations of COPD is an
important goal of disease management.2 In patients with
severe or very severeCOPDwhohave repeated exacerbations,
adding an inhaled corticosteroid (ICS) to a long-acting bron-
chodilator treatment is recommended.2 Studies have shown
benefits of regular ICS therapy relative to placebo in improving
COPD symptoms,9 reducing exacerbation frequency,10,11 and
improving quality of life.10
Treatment with budesonide/formoterol administered
via a pressurized metered-dose inhaler (pMDI) has shown
greater clinical benefits with regard to reducing COPD
symptoms and improving pulmonary function and quality of
life versus each monocomponent in a 6-month study12 and
versus formoterol in a 12-month study13 in patients with
moderate to very severe COPD. The effect of budesonide/
formoterol pMDI treatment on COPD exacerbations,
defined as a worsening of COPD requiring oral corticoste-
roid treatment, hospitalization, or both, also was assessed
in these studies.12,13 In the 12-month study, a significant
prolongation of the time to first COPD exacerbation and
reduction in exacerbation rate were observed with
budesonide/formoterol pMDI compared with formoterol
treatment. Exacerbations were assessed as a prespecified
secondary end point controlling for multiplicity of testing
in that study.13 In the 6-month study, a numerical reduc-
tion in exacerbation rate was shown for treatment with
budesonide/formoterol pMDI compared with formoterol.12
However, the 6-month study was not powered a priori for
evaluating exacerbations.12
The present randomized, double-blind, double-
dummy, 12-month clinical study was specifically designed
to compare the efficacy of 2 dosages of budesonide/
formoterol pMDI (320/9 mg twice daily and 160/9 mg twice
daily) with formoterol DPI 9 mg twice daily in preventing
exacerbations in patients with COPD. Secondary efficacy,
safety, and health economic outcomes also were
assessed.Methods
Patients
The inclusion and exclusion criteria were designed to enroll
patients with COPD who were appropriate candidates for
ICS/long-acting b2-adrenergic agonist (LABA) combination
therapy. Patients were current smokers or ex-smokers with
a smoking history of 10 pack-years, aged 40 years, with
a clinical diagnosis of COPD with symptoms for >2 years.
Patients were required to have a history of 1 COPD
exacerbation requiring treatment with a course of systemic
corticosteroids, antibiotics, or both, within 1e12 months
before screening (visit 1) and documented use of an inhaled
short-acting bronchodilator as rescue medication. At
screening, a prebronchodilator forced expiratory volume
in 1 s (FEV1) of 50% of predicted normal and a pre-
bronchodilator FEV1/forced vital capacity (FVC) of <70%
also were required. Exclusion criteria included current,
previous (within past 60 days), or planned enrollment in
a COPD pulmonary rehabilitation program, treatment with
oral corticosteroids, and incidence of a COPD exacerbation
or any other significant medical diagnosis between the
screening and randomization visits (visit 1e3). Additional
inclusion and exclusion criteria are the same as those
described in a previous study by Tashkin et al.12
Study design and treatments
This was a randomized, double-blind, double-dummy,
parallel-group, 12-month multicenter study (NCT00419744;
AstraZeneca LP D589CC00003) conducted between January
2007 and August 2009 at 180 study sites in the United States
(106 sites), Central and South America (53 sites), and South
Africa (21 sites). The study consisted of an initial screening
visit (visit 1), a 2-week run-in period (beginning at visit 2),
a 12-month randomized treatment period (visits 39), and
telephone follow-up 2 weeks after study treatment
cessation.
Before the run-in period, current COPD medications
except ICSs, including LABAs, short-acting b2-adrenergic
agonists (SABAs), short- or long-acting anticholinergics,
short-acting and slow-release oral b2-agonists, xanthine
derivatives (eg, theophylline), leukotriene antagonists or
synthase inhibitors, and ephedrine-containing medications,
were discontinued. Patients previously receiving ICS/LABA
combination treatment were switched to a comparable
dose of an ICS alone. Rescue medication (albuterol pMDI
90 mg  2 inhalations) was provided for as-needed use
during screening and run-in, and throughout the study.
After the run-in period (at visit 3), ICS therapies were dis-
continued and eligible patients who met inclusion, exclu-
sion, and randomization criteria were randomly assigned
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160/4.5 mg  2 inhalations (320/9 mg) twice daily, budeso-
nide/formoterol pMDI 80/4.5 mg  2 inhalations (160/9 mg)
twice daily, or formoterol DPI 4.5 mg  2 inhalations (9 mg)
twice daily. Assignments were made sequentially by
interactive voice response system following a computer-
generated allocation schedule produced in advance. To
maintain patient and investigator blinding, all active treat-
ments were provided in blinded treatment kits. Patients in
the budesonide/formoterol pMDI groups received a placebo
DPI and those in the formoterol DPI group received a placebo
pMDI. Additional details are included in the Supplementary
Material.
The study protocol was approved by an institutional
review board for each of the clinical sites and conducted in
accordance with the Declaration of Helsinki, Good Clinical
Practice, and applicable local regulations. Written informed
consent was obtained from patients or guardians before any
study procedures were initiated.Efficacy evaluations
The primary variable was the number of COPD exacerbations
during the randomized treatment period. Exacerbations
were defined per protocol as worsening of COPD that
required treatment with a course of oral corticosteroids,
hospitalization, or both. The time to first COPD exacerba-
tion, defined as the difference between the date of
randomization and the date of the first exacerbation, also
was assessed. Antibiotic use for COPD or potentially related
conditions (eg, respiratory infection) was not prespecified as
part of the protocol-defined COPD exacerbation. However,
a post hoc analysis of the number of COPD exacerbations
based on antibiotic use alone and a composite definition
(requiring antibiotics and/or oral corticosteroids and/or
hospitalizations) during the randomized treatment period
was performed. Subcategories of COPD exacerbations were
not mutually exclusive.
Secondary pulmonary efficacy variables included pre-
dose forced expiratory volume in 1 s (FEV1), forced vital
capacity (FVC), and morning and evening peak expiratory
flow (PEF). Spirometry measurements were conducted
according to guidelines by the American Thoracic Society
(ATS); the highest of 3 values from technically satisfactory
maneuvers was recorded.14 Secondary symptoms variables,
recorded by patients in an electronic diary, included
dyspnea, cough, and sputum scores; nighttime awakenings
caused by COPD symptoms; and rescue medication use.
Dyspnea was assessed with the validated Breathlessness
Diary.15 This single-item is derived from the Breathlessness,
Cough, and Sputum Scale and rated on a 5-point Likert-type
scale ranging from 0 to 4, with higher scores indicating
more severe symptoms.15 The percentages of awakening-
free nights and rescue medicationfree days also were
calculated. Additional details of secondary pulmonary
function and symptoms variables are included in the
Supplementary Material.
Additional secondary variables included the BODE index,
which is a composite of body mass index, airflow obstruc-
tion (percentage of predicted FEV1), dyspnea (Modified
Medical Research Council scale16), and exercise capacity (6-min walk test).17 Health-related quality of life was assessed
using the St. George’s Respiratory Questionnaire (SGRQ).18
Health care resource utilization
Details of assessment of COPD-related health care use by
patients are available in the Supplementary Material.
Safety evaluations
Safety evaluations included adverse events (AEs), discon-
tinuations due to AEs (DAEs), serious adverse events (SAEs),
vital signs, physical examinations, laboratory data (hema-
tology and chemistry), and 12-lead electrocardiograms
(ECGs). Serious AEs were defined as those that were
immediately life-threatening or resulted in death, hospi-
talization, or significantly disability. COPD signs or symp-
toms were recorded as AEs if they were serious, and/or if
they resulted in patient discontinuation from the study,
and/or if they were new to the patient or inconsistent with
the patient’s previous COPD history. Investigators assessed
the causal relationship of AEs to study medication. Clinical
laboratory data were collected at visit 2 (run-in) and visit 9
(month 12), vital signs and physical examinations were
assessed at visit 2 and each clinic visit during the random-
ized treatment period, and 12-lead ECGs were assessed at
visits 2 (run-in), 7 (month 6), and 9 (month 12).
Statistical analysis
The efficacy analysis set included all randomized patients
who received 1 dose of study medication and contributed
sufficient data for 1 efficacy end point. A sample size of
400 patients per treatment group was estimated to provide
90% power to detect a reduction from 1.07 to 0.74 in the
number of exacerbations, adjusting for a deviance of 2.3.
A closed-testing procedure was used to control for
multiplicity. If the difference between budesonide/for-
moterol pMDI 320/9 mg and formoterol for the primary
variable was statistically significant (p < 0.05), secondary
variables were tested in the following predefined order
until the first comparison did not achieve statistical
significance at the 0.05 level: 1) morning PEF, 2) evening
PEF, 3) predose FEV1, 4) dyspnea, 5) rescue medication use,
and 6) SGRQ. If each of these comparisons were significant,
then budesonide/formoterol pMDI 160/9 mg versus for-
moterol was tested in the same sequence for the primary
then secondary variables.
The mean number of exacerbations per patient-
treatment year was compared between treatment groups
using a Poisson regression model, adjusting for differential
treatment exposure, country, and over dispersion. The
COPD exacerbation rates were evaluated using the per-
protocol definition in the primary analysis and using the
composite definition, including antibiotic treatment, in the
post hoc analysis. Analysis of rates of subcategories of
COPD exacerbations (those requiring oral corticosteroids,
hospitalization, or antibiotic treatment) were not pre-
specified in the statistical analysis plan; thus, p values
associated with these variables are considered descriptive
in nature. The time to first COPD exacerbation was
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a log-rank test to compare the survival curves between
treatment groups. A Cox proportional hazards model was
used to estimate hazard ratios.
Predose pulmonary function and diary variables were
analyzed as the mean change from baseline to the mean
during the randomized treatment period (with no imputa-
tion of missing data) using an analysis of covariance
(ANCOVA) model and adjusting for treatment, country, and
baseline. The data for other time points were analyzed
similarly. Baseline was defined as the last predose value
before the first dose of randomized study treatment for
FEV1 and FVC and as the mean of the last 10 days of run-in
for diary variables.
Changes in BODE index score and SGRQ total score from
baseline (randomization) to the end of treatment were
assessed using an ANCOVA model, adjusting for treatment,
country, and baseline score. The minimal clinically impor-
tant difference (MCID) was defined as a change in SGRQ
total score of 4 units.19 Health care resource utilization
variables were analyzed as the mean number of events per
patient-treatment year for each variable, using methods
similar to those used to analyze exacerbation rates.
The safety analysis included all randomized patients
who received 1 dose of study medication and contributed
data after randomization. AEs and physical examination
results were summarized descriptively. Changes from
baseline in laboratory data, ECGs, and vital signs were
analyzed using ANCOVA, adjusting for treatment, country,
and baseline.
Results
Patients
Patient disposition is shown in Fig. 1. The discontinuation
rate during the randomized treatment period was lower inFigure 1 Patient disposition. bid, twice daily; BUD, budesonide
metered-dose inhaler.the budesonide/formoterol groups (320/9 mg: 28.7%, 160/
9 mg: 28.9%) than in the formoterol group (32.9%). Demo-
graphic and baseline characteristics generally were similar
across treatment groups (Table 1). Most patients had 1
(59.2%) or 2 (23.6%) exacerbations in the previous 12months;
the remaining 17.2% of patients had 3 exacerbations.
COPD exacerbations
For the primary variable, the number of overall protocol-
defined exacerbations per patient-treatment year was
lower with both budesonide/formoterol doses compared
with formoterol (p  0.002) (Table 2), with a 34.6%
reduction observed with budesonide/formoterol 320/9 mg
and a 25.9% reduction observed with budesonide/for-
moterol 160/9 mg compared with formoterol. Compared
with formoterol, treatment with budesonide/formoterol
320/9 mg and 160/9 mg resulted in reductions in the COPD
exacerbation rate of 34.8% and 25.9%, respectively, for
those requiring oral corticosteroids and of 26.8% and 12.2%,
respectively, for those requiring hospitalization.
Budesonide/formoterol 320/9 mg prolonged the mean
time to first protocol-defined exacerbation compared with
formoterol (277.9 days versus 249.8 days; pZ 0.029); there
was a 21.2% risk reduction observed (hazard ratio: 0.788
[95% confidence interval (CI): 0.639, 0.972]; p Z 0.026;
Fig. 2). Treatment with budesonide/formoterol 160/9 mg
resulted in numerical reductions in the mean time to first
protocol-defined exacerbation compared with formoterol
(263.7 days vs 249.8 days) and a 15.3% risk reduction
(hazard ratio: 0.847 [95% CI: 0.688, 1.043]; Fig. 2);
however, this difference was not statistically significant.
In a post hoc analysis evaluating exacerbations based on
the composite definition (antibiotics and/or oral cortico-
steroids and/or hospitalizations), the overall number of
COPD exacerbations per patient-treatment year was
reduced by 25.9% and 18.7% with budesonide/formoterol; DPI, dry powder inhaler; FM, formoterol; pMDI, pressurized
Table 1 Patient demographic and baseline clinical characteristics.
Characteristic BUD/FM pMDI FM DPI
9 mg bid
(n Z 403)
320/9 mg bid
(n Z 407)
160/9 mg bid
(n Z 408)
Men, n (%) 262 (64.4) 264 (64.7) 229 (56.8)
Age, years
Mean (SD) 63.8 (9.4) 62.8 (9.2) 62.5 (9.4)
Range 40e86 40e84 40e87
Race, n (%)
White 338 (83.0) 332 (81.4) 332 (82.4)
Black 14 (3.4) 15 (3.7) 19 (4.7)
Asian 7 (1.7) 4 (1.0) 3 (0.7)
Other 48 (11.8) 57 (14.0) 49 (12.2)
Smoking history
Ex-smoker, n (%) 269 (66.1) 265 (65.0) 249 (61.8)
Habitual smoker,a n (%) 130 (31.9) 135 (33.1) 138 (34.2)
Occasional smoker,b n (%) 8 (2.0) 8 (2.0) 16 (4.0)
Median pack-years 46 44 43
MMRC dyspnea scale, mean (SD) 2.9 (0.9) 3.0 (0.9) 3.1 (0.9)
Months since first COPD symptoms, mean (SD) 126 (86.7) 122 (81.8) 120 (86.5)
2 Exacerbations in past 1e12 months, n (%) 163 (40.0) 165 (40.4) 169 (41.9)
Most common COPD medications before run-in, n (%)
Selective b2-adrenergic agonists (includes long- and short-acting single agents) 320 (78.6) 324 (79.4) 321 (79.7)
Adrenergics/other drugs for obstructive airway diseasesc 198 (48.6) 200 (49.0) 196 (48.6)
Anticholinergics 123 (30.2) 121 (29.7) 109 (27.0)
Inhaled corticosteroids 108 (26.5) 113 (27.7) 117 (29.0)
Treated with statins (HMG-CoA reductase inhibitors) during run-in,d n (%) 71 (17.4) 76 (18.6) 58 (14.4)
% Predicted FEV1 at screening (postbronchodilator) n Z 402 n Z 398 n Z 395
Mean (SD) 37.9 (11.8) 37.6 (11.6) 37.5 (12.4)
FEV1 (L) at baseline (prebronchodilator) n Z 404 n Z 404 n Z 400
Mean (SD) 1.01 (0.43) 1.02 (0.38) 0.97 (0.40)
bid, twice daily; BUD, budesonide; COPD, chronic obstructive pulmonary disease; DPI, dry powder inhaler; FEV1, forced expiratory
volume in 1 s; FM, formoterol; HMG-CoA, 3-hydroxy-3-methyl-glutaryl-CoA; MMRC, Modified Medical Research Council; pMDI, pressurized
metered-dose inhaler; SD, standard deviation.
a Smokes 1 cigarette/day and has been smoking for 1 year before screening.
b Smokes <1 cigarette/day or has been smoking for <1 year before screening, or stopped smoking within 6 months before screening.
c Most commonly fluticasone þ salmeterol (n Z 328), ipratropium bromide þ albuterol (n Z 218), and budesonide þ formoterol
(n Z 138) (categories not mutually exclusive).
d Included simvastatin (nZ 79), atorvastatin (nZ 71), lovastatin (nZ 30), rosuvastatin (nZ 17), pravastatin (nZ 7), and fluvastatin
(n Z 4).
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respectively, compared with formoterol (1.171). However,
the number of COPD exacerbations requiring antibiotics per
patient-treatment year was higher for budesonide/for-
moterol 320/9 mg (0.229; p Z 0.031) and 160/9 mg (0.223;
pZ 0.052) compared with formoterol (0.167).Pulmonary function
Improvements from baseline to the mean during the
randomized treatment period in morning and evening PEF
were numerically greater with both budesonide/formoterol
doses compared with formoterol, but these differences
were not statistically significant (Table 3). Compared with
formoterol, improvements from baseline to the mean
during the randomized treatment period were larger with
both budesonide/formoterol doses for predose FEV1
(p  0.032). Improvements from baseline in predose FEV1also were larger with both budesonide/formoterol doses
compared with formoterol at months 1 and 2 (p  0.013)
and with budesonide/formoterol 160/9 mg compared with
formoterol at month 4 (p Z 0.040) (Fig. 3). Improvements
were numerically greatest with budesonide/formoterol
320/9 mg at end of treatment (pZ 0.091). For predose FVC,
improvements were similar for budesonide/formoterol
320/9 mg and formoterol, but greater for budesonide/for-
moterol 160/9 mg compared with formoterol (p Z 0.025)
(Table 3).COPD symptoms
Improvements from baseline to the mean during the
randomized treatment period for COPD symptom variables
(Table 4) were shown in all 3 treatment groups. Improve-
ments (ie, reductions) in sleep score and rescue medica-
tion use were greater with both budesonide/formoterol
Table 2 COPD exacerbations.
BUD/FM pMDI FM DPI
9 mg bid
(n Z 403)
320/9 mg bid
(n Z 404)
160/9 mg bid
(n Z 403)
Patients with 1 exacerbation, n (%) 169 (41.8) 173 (42.9) 182 (45.2)
Estimated total number of overall
exacerbations per patient-treatment year (SE)a
0.700 (0.084) 0.794 (0.092) 1.072 (0.119)
Treatment ratio (95% CI) vs FM DPI 9 mg 0.654 (0.535, 0.798) 0.741 (0.610, 0.899)
p Value <0.001 0.002
Estimated total number of OCS-related
exacerbations per patient-treatment year (SE)a
0.680 (0.082) 0.772 (0.090) 1.043 (0.116)
Treatment ratio (95% CI) vs FM DPI 9 mg 0.652 (0.533, 0.797) 0.741 (0.609, 0.900)
p Valueb <0.001 0.003
Estimated total number of hospitalization-related
exacerbations per patient-treatment year (SE)a
0.106 (0.014) 0.127 (0.015) 0.144 (0.016)
Treatment ratio (95% CI) vs FM DPI 9 mg 0.732 (0.522, 1.026) 0.878 (0.635, 1.215)
p Valueb 0.070 0.433
bid, twice daily; BUD, budesonide; CI, confidence interval; COPD, chronic obstructive pulmonary disease; DPI, dry powder inhaler; FM,
formoterol; OCS, oral corticosteroid; pMDI, pressurized metered-dose inhaler; SE, standard error.
a Number of exacerbations per patient-treatment year was estimated using a Poisson Regression model adjusted for differential
treatment exposure with person years as an offset variable and country.
b Analyses of subcategories of COPD exacerbations were not prespecified in the statistical analysis plan; thus, these unadjusted p
values are considered descriptive in nature.
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Table 4). Compared with formoterol, treatment with
budesonide/formoterol 320/9 mg resulted in greater
reductions in dyspnea score and improvements in rescue
medicationfree days (unadjusted p  0.026), whereas
treatment with budesonide/formoterol 160/9 mg resulted
in greater improvements from baseline in awakening-free
nights (unadjusted p Z 0.024; Table 4).
BODE index and quality of life
Improvements (ie, decreases) from baseline to the end of
treatment in the adjusted mean BODE index score were
small and similar in all 3 treatment groups (budesonide/Figure 2 KaplaneMeier probability curve for the time to first COP
BUD, budesonide; COPD, chronic obstructive pulmonary disease;
metered-dose inhaler. ap < 0.05 BUD/FM 320/9 mg vs FM.formoterol pMDI 320/9 mg, 0.38; budesonide/formoterol
160/9 mg, 0.46; formoterol, 0.34), with no significant
differences between the budesonide/formoterol groups
and the formoterol group. Mean changes from baseline to
the end of treatment in the SGRQ total score met the MCID
for a clinically meaningful improvement with all 3 treat-
ments; however, differences between treatment groups
were not statistically significant (Table 5).
Health care resource utilization
Patients treated with either budesonide/formoterol dose
had lower rates of emergency department (ED) visits,
specialist visits, primary care provider visits, other healthD exacerbation during randomized treatment. bid, twice daily;
DPI, dry powder inhaler; FM, formoterol; pMDI, pressurized
Table 3 Least squares mean changes in pulmonary function assessments from baseline to the mean during the randomized
treatment period.
Variable BUD/FM pMDI FM DPI
9 mg bid320/9 mg bid 160/9 mg bid
Morning PEF, L/minute n Z 399 n Z 397 n Z 389
Baseline mean (SD) 186.0 (70.3) 183.0 (67.8) 173.4 (65.3)
Adjusted mean change (SD) 21.2 (3.11) 20.8 (3.08) 16.7 (3.09)
Evening PEF, L/minute n Z 400 n Z 397 n Z 393
Baseline mean (SD) 194.7 (71.4) 191.6 (70.2) 183.5 (69.4)
Adjusted mean change (SD) 18.6 (3.06) 18.5 (3.03) 14.6 (3.03)
Predose FEV1, L n Z 399 n Z 399 n Z 399
Baseline mean (SD) 1.00 (0.43) 1.01 (0.37) 0.97 (0.40)
Adjusted mean change (SD) 0.07 (0.01)a 0.07 (0.01)a 0.04 (0.01)
Predose FVC, L n Z 399 n Z 399 n Z 399
Baseline mean (SD) 2.20 (0.78) 2.16 (0.69) 2.12 (0.76)
Adjusted mean change (SD) 0.08 (0.02) 0.10 (0.02)a 0.06 (0.02)
bid, twice daily; BUD, budesonide; DPI, dry powder inhaler; FEV1, forced expiratory volume in 1 s; FM, formoterol; FVC, forced vital
capacity; PEF, peak expiratory flow; pMDI, pressurized metered-dose inhaler; SD, standard deviation.
a p < 0.05 vs FM DPI 9 mg bid.
BUD/FM vs FM for preventing COPD exacerbations 263care provider home visits, and oral corticosteroid use per
patient-treatment year compared with formoterol (unad-
justed p < 0.05; Fig. 4). In addition, treatment with
budesonide/formoterol 320/9 mg resulted in reduced rates
of urgent care visits and other health care visits per
patient-treatment year compared with formoterol (unad-
justed p  0.020).Safety
The mean overall treatment exposure was similar in all
treatment groups (Table 6). Both budesonide/formoterol
doses were well tolerated relative to formoterol. The
percentage of patients with 1 AE during the randomized
treatment period was similar in all treatment groups
(Table 6), and most AEs were of mild or moderate intensity.
The most commonly reported AE was COPD, which occurred
less frequently with both budesonide/formoterol doses
compared with formoterol (Table 6). The overall incidenceFigure 3 Adjusted mean changes in predose FEV1 during the 12
budesonide; FEV1, forced expiratory volume in 1 s; FM, formoterolof AEs judged by the study investigator to be treatment-
related was higher in both budesonide/formoterol groups
(320/9 mg: 9.8%, 160/9 mg: 8.3%) than in the formoterol
group (4.7%). The incidence of individual treatment-related
AEs generally was low. Oral candidiasis was the only
treatment-related AE that occurred in 2% of patients in
any treatment group (budesonide/formoterol 320/9 mg: 9/
407 [2.2%], budesonide/formoterol 160/9 mg: 7/408 [1.7%],
formoterol: 4/403 [1.0%]).
The formoterol group had a higher incidence of DAEs
(11.7%) compared with the budesonide/formoterol 320/9-
mg (8.6%) and budesonide/formoterol 160/9-mg (8.8%)
groups. The most commonly observed DAE was COPD,
occurring in 13 patients (3.2%) in the budesonide/for-
moterol 320/9-mg group, 15 (3.7%) in the budesonide/for-
moterol 160/9-mg group, and 21 (5.2%) in the formoterol
group. Two of these COPD events were considered to be
treatment-related by the study investigator (1 in the
budesonide/formoterol 320/9-mg group and 1 in the for-
moterol group).-month randomized treatment period. ap < 0.05 vs FM. BUD,
.
Table 4 Least squares mean changes in COPD symptom variables from baseline to the mean during the randomized treatment
period.
Variable BUD/FM pMDI FM DPI
9 mg bid320/9 mg bid 160/9 mg bid
Total symptom score n Z 401 n Z 400 n Z 398
Baseline mean (SD) 4.99 (2.22) 5.12 (2.11) 5.22 (2.14)
Adjusted mean change (SD) 1.06 (0.12) 1.08 (0.12) 0.96 (0.12)
Dyspnea score n Z 401 n Z 400 n Z 398
Baseline mean (SD) 1.81 (0.81) 1.84 (0.77) 1.91 (0.73)
Adjusted mean change (SD) 0.39 (0.05)a 0.36 (0.05) 0.29 (0.05)
Cough score n Z 401 n Z 400 n Z 398
Baseline mean (SD) 1.74 (0.83) 1.82 (0.78) 1.81 (0.81)
Adjusted mean change (SD) 0.42 (0.05) 0.45 (0.04) 0.41 (0.05)
Sputum score n Z 401 n Z 400 n Z 398
Baseline mean (SD) 1.45 (0.86) 1.46 (0.83) 1.50 (0.87)
Adjusted mean change (SD) 0.25 (0.04) 0.26 (0.04) 0.27 (0.04)
Sleep score n Z 400 n Z 398 n Z 395
Baseline mean (SD) 1.12 (0.88) 1.19 (0.85) 1.24 (0.88)
Adjusted mean change (SD) 0.32 (0.04)a 0.32 (0.04)a 0.24 (0.04)
% Awakening-free nights n Z 401 n Z 401 n Z 399
Baseline mean (SD) 39.4 (38.8) 35.0 (37.8) 33.8 (37.0)
Adjusted mean change (SD) 10.1 (2.26) 11.3 (2.23)a 6.7 (2.23)
Rescue medication use,
inhalations/day
n Z 401 n Z 401 n Z 399
Baseline mean (SD) 5.8 (4.6) 6.1 (5.1) 6.0 (4.5)
Adjusted mean change (SD) 1.5 (0.26)b 1.2 (0.26)b 0.5 (0.26)
% Rescue medicationfree days n Z 401 n Z 401 n Z 399
Baseline mean (SD) 12.9 (28.9) 10.8 (27.3) 11.4 (27.2)
Adjusted mean change (SD) 13.1 (2.25)b 11.4 (2.23) 7.5 (2.23)
bid, twice daily; BUD, budesonide; COPD, chronic obstructive pulmonary disease; DPI, dry powder inhaler; FM, formoterol; pMDI,
pressurized metered-dose inhaler; SD, standard deviation.
a p < 0.05 vs FM DPI 9 mg bid.
b p < 0.01 vs FM DPI 9 mg bid.
264 A. Sharafkhaneh et al.A total of 198 patients experienced nonfatal SAEs during
the randomized treatment period: 76/407 (18.7%) in the
budesonide/formoterol 320/9-mg group, 54/408 (13.2%) in
the budesonide/formoterol 160/9-mg group, and 68/403Table 5 Least squares mean changes in SGRQ total and domain
Score
320/9 mg bid
Total n Z 375
Baseline mean (SD) 55.9 (17.6)
Adjusted mean change (SD) 7.2 (1.18)
Symptoms n Z 375
Baseline mean (SD) 64.6 (20.5)
Adjusted mean change (SD) 14.5 (1.58)
Activity n Z 376
Baseline mean (SD) 71.7 (18.0)
Adjusted mean change (SD) 6.8 (1.30)
Impacts n Z 376
Baseline mean (SD) 44.0 (20.8)
Adjusted mean change (SD) 5.6 (1.37)
bid, twice daily; BUD, budesonide; DPI, dry powder inhaler; FM, fo
deviation; SGRQ, St. George’s Respiratory Questionnaire.(16.9%) in the formoterol group. Three of these nonfatal
SAEs were considered by the study investigator to be
treatment-related: 2 SAEs of atrial fibrillation (1 in each of
the budesonide/formoterol groups) and 1 SAE of COPD inscores from baseline to end of treatment.
BUD/FM pMDI FM DPI
9 mg bid160/9 mg bid
n Z 366 n Z 357
57.8 (16.7) 58.6 (16.9)
5.5 (1.17) 5.9 (1.17)
n Z 370 n Z 360
65.1 (18.0) 66.4 (19.1)
11.3 (1.56) 11.8 (1.56)
n Z 366 n Z 358
73.6 (18.0) 74.3 (18.9)
5.3 (1.29) 5.6 (1.29)
n Z 368 n Z 360
46.3 (20.2) 47.2 (20.0)
4.0 (1.36) 4.5 (1.36)
rmoterol; pMDI, pressurized metered-dose inhaler; SD, standard
Figure 4 Treatment ratios for events of resource utilization per patient-treatment year. ap < .05 vs FM. BUD, budesonide; CI,
confidence interval; ED, emergency department; FM, formoterol; OCS, oral corticosteroid; PCP, primary care provider.
BUD/FM vs FM for preventing COPD exacerbations 265the formoterol group. Twenty-six patients experienced
SAEs leading to death during the randomized treatment
period: 7 in the budesonide/formoterol 320/9-mg group; 9
in the budesonide/formoterol 160/9-mg group; and 10 in the
formoterol group. None of the deaths were considered to
be treatment-related by the investigator.
Pneumonia-related AEs occurred in 6.4% (26/407), 4.7%
(19/408), and 2.7% (11/403) of patients in the budesonide/
formoterol 320/9, 160/9, and formoterol groups, respec-
tively; the overall incidence of pneumonia-related AEs was
low (4.6%). The most commonly reported pneumonia-
related AE was bacterial pneumonia (Table 7). SAEs of
pneumonia occurred in 3.2% (13/407), 1.0% (4/408), and
1.7% (7/403) of patients in the budesonide/formoterol 320/
9, 160/9, and formoterol groups, respectively. One patientTable 6 Overall adverse events reported by 5% of patients in
Variable
320/9
(n Z
Mean exposure (SD), wk 42.4 (
Adverse event, n (%)
Any adverse event 308 (
COPD 85 (
Headache 56 (
Nasopharyngitis 31 (
Bronchitis 37 (
Influenza 29 (
Back pain 21 (
Bacterial upper respiratory tract infection 18 (
Sinusitis 18 (
Viral upper respiratory tract infection 21 (
Hypertension 21 (
bid, twice daily; BUD, budesonide; COPD, chronic obstructive pulm
pressurized metered-dose inhaler; SD, standard deviation.in the budesonide/formoterol 160/9 group experienced an
SAE of pneumonia leading to death during the randomized
treatment period. None of the SAEs of pneumonia were
considered treatment-related by the investigator.
Cardiac-related AEs occurred more frequently in the
budesonide/formoterol groups (320/9 mg: 12.3%, 160/9 mg:
9.6%) than in the formoterol group (6.9%). Hypertension was
the most common cardiac-related AE: budesonide/formoterol
320/9mg: 21/407 (5.2%), budesonide/formoterol 160/9mg: 15/
408 (3.7%), formoterol: 8/403 (2.0%). All other individual
cardiac-related AEs occurred at an incidence of <2.0%.
No clinically meaningful or statistically significant differ-
enceswereobservedbetween the treatment groups formean
changes from baseline to the end of month 12 in systolic or
diastolic bloodpressure (Supplemental Table E1). Therewereany treatment group.
BUD/FM pMDI FM DPI
9 mg bid
(n Z 403)
mg bid
407)
160/9 mg bid
(n Z 408)
16.8) 41.4 (17.6) 40.2 (18.3)
75.7) 295 (72.3) 304 (75.4)
20.9) 76 (18.6) 95 (23.6)
13.8) 46 (11.3) 43 (10.7)
7.6) 35 (8.6) 41 (10.2)
9.1) 32 (7.8) 28 (6.9)
7.1) 26 (6.4) 25 (6.2)
5.2) 18 (4.4) 21 (5.2)
4.4) 24 (5.9) 17 (4.2)
4.4) 19 (4.7) 20 (5.0)
5.2) 14 (3.4) 14 (3.5)
5.2) 16 (3.9) 9 (2.2)
onary disease; DPI, dry powder inhaler; FM, formoterol; pMDI,
Table 7 Number (%) of patients with pneumonia adverse events.
Adverse event
BUD/FM pMDI FM DPI
9 mg bid
(n Z 403)
320/9 mg bid
(n Z 407)
160/9 mg bid
(n Z 408)
Patients with any pneumonia adverse event 26 (6.4) 19 (4.7) 11 (2.7)
Bacterial pneumonia 18 (4.4) 14 (3.4) 9 (2.2)
Pneumonia 5 (1.2) 2 (0.5) 0
Lobar pneumonia 2 (0.5) 2 (0.5) 2 (0.5)
Bronchopneumonia 1 (0.2) 0 0
Staphylococcal pneumonia 0 1 (0.2) 0
Pneumonitis 0 0 1 (0.2)
bid, twice daily; BUD, budesonide; DPI, dry powder inhaler; FM, formoterol; pMDI, pressurized metered-dose inhaler.
266 A. Sharafkhaneh et al.no clinically meaningful differences between the treatment
groups formeanchanges frombaseline to theendofmonth12
in pulse rate; however, the difference between the budeso-
nide/formoterol 160/9-mg group and the formoterol group
was statistically significant (pZ 0.012; Supplemental Table
E1). The percentages of patients with clinically important
abnormalities in blood pressure and pulse are shown in
Supplemental Table E2. No clinically meaningful or statisti-
cally significant differences were observed among the
treatment groups for mean changes from baseline to the end
of treatment in heart rate, QT interval, QTc (Bazett’s)
interval, or QTc (Fredericia’s) interval (Supplemental Table
E3). Additionally, no clinically meaningful differences in
clinical laboratory data or physical examination findingswere
noted among the treatment groups.Discussion
This study is the first designed specifically to evaluate the
long-term effect of budesonide/formoterol pMDI on COPD
exacerbations relative to formoterol alone. In this study,
the percentage of patients experiencing a COPD exacer-
bation, defined as a worsening of COPD requiring the use of
oral corticosteroids, hospitalization, or both, and the total
number of overall exacerbations per patient-treatment
year, were lower in both budesonide/formoterol pMDI
groups compared with the formoterol group. These findings
were largely driven by the number of COPD exacerbations
requiring treatment with oral corticosteroids, which were
lower for both budesonide/formoterol pMDI doses
compared with formoterol. Moreover, budesonide/for-
moterol pMDI 320/9 mg significantly prolonged the time to
first exacerbation compared with formoterol.
The reduction in thenumber of exacerbationsper patient-
treatment year for budesonide/formoterol pMDI versus for-
moterol from the present study were consistent with those
from studies of budesonide/formoterol DPI versus for-
moterol20,21 and confirmed the results of previous studies
evaluating the effect of budesonide/formoterol pMDI on
COPD exacerbations as a secondary outcome.12,13 The 26%e
35% reduction in overall exacerbations per patient-
treatment year (primary end point) observed with both
budesonide/formoterol pMDI doses relative to formoterol
were similar to those reported previously for budesonide/formoterol pMDI relative to formoterol (20%e29%)12,13 and
for fluticasone propionate/salmeterol relative to salmeterol
(12%e31%).22e24 Additionally, budesonide/formoterol pMDI
320/9 mg significantly prolonged the time to first exacerba-
tion (secondary end point) relative to formoterol by 21%,
which also was similar to the 25%e27% reduction in risk
associated with fluticasone propionate/salmeterol
compared with salmeterol.22,23 In this study, a third of
patients were receiving ICS before study enrollment, and it is
unclear whether discontinuation of ICS in those patients who
were randomized to receive formoterol alone could have
contributed to worse exacerbation outcomes in the for-
moterol group compared with the budesonide/formoterol
group. Because such qualitative data were not collected
before study entry, it is impossible to determine the effect of
prestudy ICS discontinuation on COPD exacerbations in
patients randomized to the formoterol group. Overall, these
results demonstrated that ICS/LABA combination treatment
provides clinical benefits beyond a LABA alone in the
management of COPD exacerbations, supporting the use of
ICS/LABA combination treatments in patients with COPD and
a history of previous exacerbations.
Comparison of the exacerbation findings from the present
study with previous studies is limited because different COPD
exacerbation definitionsmay have been used. A standardized
definition has not been established but definitions can be
symptom-based or event-based.1 Symptom-based definitions
typically describe COPD exacerbations as worsening of
dyspnea and increased sputum production or purulence.1
Event-based definitions, such as the one used in the present
study, rely on hospitalization or changes in COPD treatment,
particularly use of antibiotics or oral corticosteroids.1
However, patients’ assessments of symptoms generally are
considered by physicians when making decisions about
changes in treatment regimens or whether hospitalization is
required. In the present study, patients’ perception of COPD
deterioration prompted a call to the study investigator.
Although event-based definitions may fail to capture some
symptom-related exacerbations, and therefore may result in
under-reporting of exacerbations, they are a practical
method of identifying COPD exacerbations in the clinical
setting.25 In addition, an event-based method of capturing
exacerbations is less ambiguous than symptom-based
methods, which commonly are based on patient diaries and
subjective assessments of symptoms.1,25
BUD/FM vs FM for preventing COPD exacerbations 267The present study also evaluated other secondary vari-
ables such as pulmonary function, COPD symptoms, the
BODE, index, quality of life, and health care resource
utilization. Both budesonide/formoterol pMDI doses resul-
ted in nonsignificant improvements in morning PEF
compared with formoterol. According to the prespecified
multiplicity rule, p values for the remaining secondary
efficacy variables, evening PEF, predose FEV1, dyspnea,
rescue medication use, and SGRQ, were unadjusted and to
be interpreted as descriptive in nature. Previous studies
have shown that both doses of budesonide/formoterol pMDI
significantly improved morning and evening PEF compared
with formoterol.12,13 In the present study, both budeso-
nide/formoterol pMDI doses demonstrated improvements in
morning and evening PEF similar to previous studies, but
the magnitude of improvement observed for formoterol
was approximately 1.5 times greater for morning PEF and 2
times greater for evening PEF in the present study
compared with previously conducted studies.12,13 A poten-
tial reason for this difference is that the baseline morning
and evening PEF values were lower in the formoterol groups
in the present study (173 L/min and 184 L/min, respec-
tively) than in the previously reported COPD studies
(183e185 L/min and 192e194 L/min, respectively).12,13 The
large formoterol effect in the present study may explain
why improvements with the combination product were not
significant compared with the formoterol group.
The incidence of pneumonia-related AEs was higher in
both budesonide/formoterol pMDI groups compared with
the formoterol group, and in the budesonide/formoterol
pMDI 320/9-mg group compared with the budesonide/for-
moterol pMDI 160/9-mg group. These findings are inconsis-
tent with previous COPD studies of budesonide/formoterol
pMDI12,13 and budesonide/formoterol DPI21 that showed no
differences in the incidence of pneumonia between the
budesonide/formoterol groups and the formoterol group,
but are similar to findings from fluticasone propionate/
salmeterol studies, which have consistently shown an
increased incidence of pneumonia when compared with
salmeterol treatment.23,24,27 A meta-analysis of data from
7 COPD studies of 6 months (N Z 7042) showed no
increase in the risk of pneumonia reported as an AE for
budesonide treatment given with or without a LABA.26 The
percentage of patients with pneumonia-related AEs in the
meta-analysis (3.0%)26 is similar to that in the formoterol
treatment group (2.7%) in the present study.
A limitation of the pneumonia findings from both the
present and previous studies is that a diagnosis of pneu-
monia typically was based on clinical judgment and not
radiological or microbiological assessments. Reported SAEs
of pneumonia, which were associated with hospitalization,
were more likely to have been confirmed by chest radio-
graph than AEs of pneumonia, which were likely managed in
an outpatient setting. In this study, no differences in the
incidence of SAEs of pneumonia or deaths due to pneu-
monia were shown between the budesonide/formoterol
pMDI groups and the formoterol group. These findings are
consistent with previous COPD studies of budesonide/for-
moterol pMDI.12,13
Other tolerability results in the present study generally
were consistent with those from previously conducted
budesonide/formoterol pMDI studies.12,13 The incidence ofAEs was generally similar across the 3 treatment groups, and
treatment-related AEs occurred at a low frequency.
Although the incidence of individual cardiac-related AEs was
low, the percentage of patients with any cardiac-related AE
was slightly higher for both budesonide/formoterol doses
than for formoterol. Fewer patients discontinued the study
because of AEs in the budesonide/formoterol pMDI treat-
ment groups than in the formoterol group. There also were
lower rates of COPD-related AEs leading to discontinuation
with budesonide/formoterol pMDI.
Conclusions
In summary, both budesonide/formoterol pMDI doses
significantly reduced the number of overall exacerbations
per patient-treatment year compared with formoterol. In
addition, both doses of budesonide/formoterol pMDI were
well tolerated during 1 year of treatment. Apart from the
somewhat elevated incidence of pneumonia in the budes-
onide/formoterol pMDI groups compared with the formot-
erol group, overall safety profiles were similar to that of
formoterol and commensurate with previously reported
data for ICS/LABA therapy.
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